Warner Chilcott

Warner Chilcott was a mid-size specialty pharmaceutical company focused on developing, manufacturing, and marketing branded prescription pharmaceutical products. The company was primarily focused on women's healthcare, dermatology, gastroenterology, and urology markets in North America. With over 400 dedicated specialty sales representatives, Warner Chilcott established strong market franchises in women's health through precision marketing and targeted sales strategies. Founded in 1968 as Galen, a sales and marketing organization in the UK and Ireland, the company was renamed Warner Chilcott in 2004 to reflect its strategic pivot toward the U.S. market. In 2009, the company acquired Procter & Gamble's global pharmaceuticals business for $3.1 billion, significantly expanding its portfolio and acquiring manufacturing facilities in Puerto Rico and Germany. This acquisition included key products like Actonel and Enablex, plus approximately 2,300 employees. By 2013, Warner Chilcott had established itself as a leading specialty pharmaceutical player with annual revenues exceeding $800 million and a portfolio of approximately 61 clinical trials across its pipeline. The company's therapeutic focus centered on women's contraceptive, hormone replacement, and osteoporosis treatments, along with urology and dermatology products.